- Home
- TAK vs TCOM Comparison
TAK vs TCOM Comparison
Compare TAK & TCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAK | TCOM |
|---|---|---|
| Founded | 1781 | 1999 |
| Country | Japan | Singapore |
| Employees | 47455 | 41073 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.1B | 34.2B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TAK | TCOM |
|---|---|---|
| Price | $17.86 | $54.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $78.33 |
| AVG Volume (30 Days) | 2.4M | ★ 3.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.97% | 0.58% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.04 | $15.65 |
| Revenue Next Year | $0.92 | $12.92 |
| P/E Ratio | $41.25 | ★ $9.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.99 | $49.48 |
| 52 Week High | $18.82 | $79.00 |
Technical Indicators
Market Signals| Indicator | TAK | TCOM |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 42.44 |
| Support Level | $14.78 | N/A |
| Resistance Level | $18.82 | $64.47 |
| Average True Range (ATR) | 0.24 | 1.51 |
| MACD | -0.18 | 0.33 |
| Stochastic Oscillator | 26.30 | 63.26 |
Price Performance
Historical ComparisonAbout TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About TCOM Trip.com Group Limited
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 79% of sales from accommodation reservations and transportation ticketing in 2024. The rest of revenue comes from package tours and corporate travel. Before the pandemic in 2019, the company generated 25% of revenue from international travel, which is important to its margin expansion. Most of sales come from its domestic platform, but the company is expanding its overseas business. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Tongcheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.